Results 181 to 190 of about 130,501 (296)

Cyclins and cdks in development and cancer: a perspective

open access: yesOncogene, 2005
Amit M. Deshpande, P. Sicinski, P. Hinds
semanticscholar   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

open access: yesInternational Journal of Cancer, EarlyView.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching   +20 more
wiley   +1 more source

MEIOC prevents continued mitotic cycling and promotes meiotic entry during mouse oogenesis. [PDF]

open access: yesDevelopment
Ushuhuda EG   +5 more
europepmc   +1 more source

Cyclins and cell cycle control in cancer and disease.

open access: yesGenes & cancer, 2012
Mathew C. Casimiro   +4 more
semanticscholar   +1 more source

PVT1 lincRNA signals an androgen‐dependent transcriptional activation program of oncogenes in prostate cancer cells

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Unraveling the networks that regulate androgen receptor (AR) function is critical to better understanding prostate cancer development and progression. Of particular interest in this regard is the long non‐coding RNA PVT1, which regulates gene expression in cancer and is upregulated in prostate tumors.
Maria Gabriela Berzoti‐Coelho   +7 more
wiley   +1 more source

Tumor‐educated platelets in cancer diagnostics and prognostics: A critical appraisal and roadmap for clinical translation

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Tumor‐educated platelets (TEPs) are emerging as a compelling frontier in liquid biopsy, functioning as dynamic, systemic sensors that sequester and process tumor‐derived biomolecules. This interaction imprints an integrated molecular signature of malignancy—spanning the transcriptome, proteome, lipidome, and crucially, the captured genome ...
Whi‐An Kwon   +5 more
wiley   +1 more source

Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised Cancers. [PDF]

open access: yesJ Med Chem
Shapiro JA   +35 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy